Complete responses and survival after polychemotherapy plus interferon-α for patients with metastatic melanoma

Melanoma Research

Volumn 6, Issue 4, 1996, Pages 331-336

  Vuoristo, M S ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Chemo immunotherapy; Complete response; Interferon; Melanoma; Survival

Indexed keywords

BLEOMYCIN; DACARBAZINE; LOMUSTINE; NIMUSTINE; PROCARBAZINE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; SURVIVAL TIME;

EID: 0029788056     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199608000-00009     Document Type: Article

References (34)

1. Teppo L, Hakulinen T, Luostarinen T, et al. The prognosis of Finnish cancer patients [in Finnish]. Duodecim 1993; 109: 917-925.
2. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16 (Suppl. 1): 34-44.
3. Buzaid AC, Murren J. Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 1992; 21: 205-209.
4. Aapro MS. Advances in systemic treatment of malignant melanoma. Eur J Cancer 1993; 29A: 613-617.
5. Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CDV) for metastatic melanoma. Cancer 1989; 64: 2024-2029.
6. Ringborg U, Jungnelius U, Hansson J, et al. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. Am J Clin Oncol 1990; 13: 214-217.
7. Stables GI, Doherty VR, MacKie RM. Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. Br J Dermatol 1992; 127: 505-508.
8. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebal metastases. Cancer 1990; 66: 1873-1878.
9. Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med 1995; 332: 1004-1014.
10. Kellokumpu-Lehtinen P, Toivanen A, Nordman E. Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effect of treatment on immunological functions. Cancer Immunol Immunother 1989; 28: 212-216.
11. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon α2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-1408.
12. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.
13. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10: 1919-1926.
14. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemo-immunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
15. Atkins MB, O'Boyle KR, Sosman JA, et al. Multi-institutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553-1560.
16. Ron IG, Inbar MJ, Gutman M, et al. Recombinant interferon α-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients. Cancer Immunol Immunother 1993; 37: 61-66.
17. Mulder NH, van der Graaf WTA, Willemse PHB, et al. Dacarbazine (DTIC)-based chemotherapy or chemo-immunotherapy of patients with disseminated malignant melanoma. Br J Cancer 1994; 70: 681-683.
18. Lakhani S, Selby P, Bliss JM, et al. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer 1990; 61: 330-334.
19. Thomson DB, Adena M, McLeod GRC, et al. Interferon-α-2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-138.
20. Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon-α-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-811.
21. Gröhn P, Kumpulainen E, Nuortio L, et al. A phase II study of metastatic melanoma treated with a combination of interferon α-2b, dacarbazine and nimustine. Eur J Cancer 1992; 28: 441-443.
22. Vuoristo M, Gröhn P, Kumpulainen E, et al. Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-α. Eur J Cancer 1994; 30A: 420.
23. Vuoristo M-S, Gröhn P, Kellokumpu-Lehtinen P, et al. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 1995; 121: 175-180.
24. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
25. Ahmann DL, Creagan ET, Hahn RG, et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63: 224-227.
26. Fields KK. Autologous bone marrow transplantation and melanoma: a focused review of the literature. Ann Plast Sug 1992; 28: 70-73.
27. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
28. Joensuu H. Association between chemotherapy response and rate of disease progression in disseminated melanoma. Br J Cancer 1991; 63: 154-156.
29. Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992; 127: 1303-1308.
30. Balch CM, Soong S-J, Murad TM, et al. A multifactorial analysis of melanoma. J Clin Oncol 1983; 1: 126-134.
31. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005.
32. Sirott MN, Bajorin DF, Wong GYC, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 3091-3098.
33. Harning R, Mainolfi E, Bystryn J-C, et al. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 1991; 51: 5003-5005.
34. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69: 911-913.